Ritter Pharmaceuticals Announces Collaboration with University of Nebraska to Explore Development of Microbiome Therapeutics ...
24 January 2017 - 1:00AM
Marketwired
Ritter Pharmaceuticals Announces Collaboration with University
of Nebraska to Explore Development of Microbiome Therapeutics in
Metabolic Syndrome
LOS ANGELES, CA-(Marketwired - Jan 23, 2017) - Ritter
Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or
the "Company"), a pharmaceutical company developing novel
therapeutic products that modulate the human gut microbiome to
treat gastrointestinal diseases, today announced that it is
collaborating with the newly-established Food for Health Center at
the University of Nebraska ("NU") to study the role of the
microbiome and RP-G28 in metabolic syndrome.
As part of the collaboration, Dr. Amanda Ramer-Tait at NU and
Jens Walter, University of Alberta, two leading scientists in the
fields of gut health and microbiome research, plan to conduct
research exploring the microbiome's role in metabolic syndrome. The
pre-clinical research is designed to build upon previously
published studies suggesting that prebiotics may support
improvements in clinical measurements associated with metabolic
syndrome. Ritter Pharmaceuticals is providing its lead compound,
RP-G28, for use in the study. RP-G28 is currently in a Phase 2b/3
study in humans for the treatment of lactose intolerance. In
previous human studies, RP-G28 has demonstrated significant
beneficial changes to the gut microbiome that have been associated
with supporting metabolic health.
Andrew J. Ritter, Co-founder and President of Ritter
Pharmaceuticals, added, "we are pleased to be collaborating on such
forward-thinking research that could expand our understanding of
the role of the microbiome and RP-G28 in improving clinical
parameters of metabolic syndrome. Furthermore, we're excited to
explore other indications where RP-G28 may be efficacious."
Dr. Ramer-Tait, the Harold and Esther Edgerton Assistant
Professor of Immunology and Microbiology at the University of
Nebraska-Lincoln, added, "We are grateful to Ritter Pharmaceuticals
for providing RP-G28 so we can study how manipulation of the
microbiome may impact metabolic syndrome. There is great potential
to take prebiotic-based gut microbiota modulators and explore how
they may help improve human health."
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc. (www.RitterPharma.com) develops
novel therapeutic products that modulate the gut microbiome to
treat gastrointestinal diseases. Its lead product, RP-G28, has the
potential to become the first FDA-approved treatment for lactose
intolerance, a condition that affects millions worldwide. The
company is further exploring the functionality and discovering the
therapeutic potential gut microbiome changes may have on
treating/preventing a variety of conditions including:
gastrointestinal diseases, immuno-oncology, metabolic, and liver
disease.
About the University of Nebraska and the Food for Health Center
at the University of Nebraska
The Food for Health Center at the University of Nebraska is a
multidisciplinary initiative that unites Nebraska's strengths in
gastrointestinal and biomedical research with production
agriculture and plant/animal breeding/genetics. Importantly, NU is
focused on establishing a comprehensive research platform to
develop: (1) food crops bred for proven health promotion and
agronomic traits, (2) foods and food ingredients with predictable,
clinically-proven effects on the microbiome and host metabolic and
inflammatory characteristics, and (3) prebiotics with predictable,
clinically proven effects on gastrointestinal characteristics
and/or metabolic and inflammatory characteristics.
Forward-Looking Statements
This release may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including statements related to our ability to bring RP-G28 to
market. Management believes that these forward-looking statements
are reasonable as and when made. However, such statements involve a
number of known and unknown risks and uncertainties that could
cause the Company's future results, performance or achievements to
differ significantly from the results, performance or achievements
expressed or implied by such forward-looking statements. These
risks and uncertainties include, but are not limited to, risks
associated with the drug development process generally, including
the outcomes of planned clinical trials and the regulatory review
process. For a discussion of certain risks and uncertainties
affecting Ritter Pharmaceuticals' forward-looking statements,
please review the Company's reports filed with the Securities and
Exchange Commission, including, but not limited to, its Annual
Report on Form 10-K for the period ended December 31, 2015 and
Quarterly Reports on Form 10-Q for the periods ended March 31,
2016, June 30, 2016 and September 30, 2016. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of the date on which they are made. These
statements are based on management's current expectations and
Ritter Pharmaceuticals does not undertake any responsibility to
revise or update any forward-looking statements contained herein,
except as expressly required by law.
Contacts Ellen Mochizuki 310-203-100 ellen@ritterpharma.com
Ritter Pharmaceuticals (NASDAQ:RTTR)
Historical Stock Chart
From Apr 2024 to May 2024
Ritter Pharmaceuticals (NASDAQ:RTTR)
Historical Stock Chart
From May 2023 to May 2024